東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

ANDA suitability petitions: The proc...

Cottrell, Sandra C.

FindBook

Google Book

Amazon

博客來

ANDA suitability petitions: The process of extending generic eligibility as part of the Drug Price Competition-Patent Term Restoration Act of 1984. An analysis of data from enactment through December, 1989.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	ANDA suitability petitions: The process of extending generic eligibility as part of the Drug Price Competition-Patent Term Restoration Act of 1984. An analysis of data from enactment through December, 1989./
作者:	Cottrell, Sandra C.
面頁冊數:	423 p.
附註:	Source: Dissertation Abstracts International, Volume: 57-01, Section: B, page: 0263.
Contained By:	Dissertation Abstracts International57-01B.
標題:	Health Sciences, Pharmacy. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=9227447

ANDA suitability petitions: The process of extending generic eligibility as part of the Drug Price Competition-Patent Term Restoration Act of 1984. An analysis of data from enactment through December, 1989.
Cottrell, Sandra C.

ANDA suitability petitions: The process of extending generic eligibility as part of the Drug Price Competition-Patent Term Restoration Act of 1984. An analysis of data from enactment through December, 1989. - 423 p.

Source: Dissertation Abstracts International, Volume: 57-01, Section: B, page: 0263.

Thesis (Ph.D.)--Temple University, 1992.

On September 24, 1984, the Drug Price Competition--Patent Term Restoration (DPC-PTR) Act (Pub. L 98-417) was signed into law, amending section 505 of the Food, Drug, and Cosmetic Act (21 U.S.C. 355). The amendment represented the culmination of Congressional efforts to achieve two distinct and, in principle, opposing objectives: to provide a mechanism to assure the timely marketing of generic versions of brand name drugs, and to provide increased incentives for pioneer drug research and development, which would help to offset the increased expenditure of time and resources necessary to bring a new drug to market. Within the complexity of this legislation, there is a specific mechanism for a potential generic manufacturer to make modifications of a generic drug product qualify for an abbreviated regulatory process which would not otherwise be eligible for such a process. This mechanism utilizes a suitability (deviation) petition to which, by regulation, the Food and Drug Administration is to respond within 90 days of application.Subjects--Topical Terms:

1017737
Health Sciences, Pharmacy.

ANDA suitability petitions: The process of extending generic eligibility as part of the Drug Price Competition-Patent Term Restoration Act of 1984. An analysis of data from enactment through December, 1989.
LDR:02576nmm 2200289 4500 001 1852347
005 20051230065948.5
008 130614s1992 eng d
035 $a (UnM)AAI9227447
035 $a AAI9227447
040 $a UnM $c UnM
100 1 $a Cottrell, Sandra C. $3 1940209
245 1 0 $a ANDA suitability petitions: The process of extending generic eligibility as part of the Drug Price Competition-Patent Term Restoration Act of 1984. An analysis of data from enactment through December, 1989.
300 $a 423 p.
500 $a Source: Dissertation Abstracts International, Volume: 57-01, Section: B, page: 0263.
500 $a Major Adviser: Murray Tuckerman.
502 $a Thesis (Ph.D.)--Temple University, 1992.
520 $a On September 24, 1984, the Drug Price Competition--Patent Term Restoration (DPC-PTR) Act (Pub. L 98-417) was signed into law, amending section 505 of the Food, Drug, and Cosmetic Act (21 U.S.C. 355). The amendment represented the culmination of Congressional efforts to achieve two distinct and, in principle, opposing objectives: to provide a mechanism to assure the timely marketing of generic versions of brand name drugs, and to provide increased incentives for pioneer drug research and development, which would help to offset the increased expenditure of time and resources necessary to bring a new drug to market. Within the complexity of this legislation, there is a specific mechanism for a potential generic manufacturer to make modifications of a generic drug product qualify for an abbreviated regulatory process which would not otherwise be eligible for such a process. This mechanism utilizes a suitability (deviation) petition to which, by regulation, the Food and Drug Administration is to respond within 90 days of application.
520 $a After a relevant review of the history of the Act and the details of the DPC-PTR Act of 1984, this dissertation examines how industry, collectively, is using this petitioning process and how the FDA is responding. To achieve this objective, all suitability petitions which have been submitted since enactment, through December, 1989, were entered into a computer data base. The petitions were analyzed in order to examine FDA's and industry's responses to this feature of the legislation. $\ sp* $ ftn $\ sp*
590 $a School code: 0225.
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Political Science, Public Administration. $3 1017438
650 4 $a Law. $3 600858
690 $a 0572
690 $a 0617
690 $a 0398
710 2 0 $a Temple University. $3 959342
773 0 $t Dissertation Abstracts International $g 57-01B.
790 1 0 $a Tuckerman, Murray, $e advisor
790 $a 0225
791 $a Ph.D.
792 $a 1992
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=9227447